secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2026-10-06T12:00:29+00:00
Accession:  0001493152-26-045860
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 3.02, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Telomir raises $5.6M in common-stock PIPE at $1.16/share; DeJoria adds $1.0M
----------------------------------------------------------------------------

- PIPE of 4,843,300 common shares at $1.16/share, a 5% discount to the 10-day VWAP ending two days before the Oct. 5, 2026 closing; gross proceeds ~$5.6M.
- Existing significant shareholder John Paul DeJoria (reported ~3.55M shares, ~5.0% of outstanding) invested an additional $1.0M; other existing and new investors also participated.
- Alexander Capital placed the deal: 9.0% cash fee (~$455,000), expense reimbursement capped at $40,000, plus 387,464 five-year warrants at $1.16/share.
- Net proceeds fund Telomir-Zn's Phase 1/2 trial in advanced or metastatic triple-negative breast cancer under an FDA-cleared IND, plus working capital and general corporate purposes.
- No investor warrants, convertibles or price-reset features; Telomir must file a resale registration statement within 30 days of closing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226045860/0001493152-26-045860-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000149315226045860/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-045860

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer